A new tool for estimating liver cancer risk after a hepatitis C virus cure

作     者：Hamish Innes William L.Irving 

作者机构：School of Health and Life SciencesGlasgow Caledonian UniversityGlasgowUK NIHR Nottingham Biomedical Research CentreNottingham University Hospitals NHS Trust and the University of NottinghamNottinghamUK 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2020年第9卷第6期

页      面：791-793页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：liver cirrhosis hepatitis 

摘      要：Chronic hepatitis C virus(HCV)infection frequently leads to liver cirrhosis(1),which is a major risk factor for hepatocellular carcinoma(HCC)and liver ***,these two complications account for nearly half a million HCV-related deaths every year,world-wide(2).In contrast to other blood borne viruses such as HIV and hepatitis B,chronic HCV is a curable *** until recently,few HCV cirrhosis patients were able to achieve a cure because standard-of-care therapies were ineffective(30%chance of cure)and entailed significant adverse effects(3).